已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract LB_C09: QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity

阿法替尼 克拉斯 西妥昔单抗 埃罗替尼 表皮生长因子受体抑制剂 癌症研究 体内 药理学 癌症 表皮生长因子受体 生物 医学 结直肠癌 内科学 生物技术
作者
Yang J. Zhang,Jillian M. Silva,Yang W. Zhang,Elizabeth Donohue Vo,John M. Micozzi,Douglas Krauth,Arghyotri Sinha,Ben Reid,Brooke McDonough,Gregory M. Lee,Christopher C. Pan,Audrey Hospital,Juan I. Luengo,Cameron Pitt,Hong Lin
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): LB_C09-LB_C09 被引量:1
标识
DOI:10.1158/1535-7163.targ-23-lb_c09
摘要

Abstract KRAS, one of the most frequently mutated oncogenes in cancer, was considered undruggable until the development of covalent KRASG12C inhibitors. While these KRASG12C-targeted therapies exhibit clinical benefit, they do not address the most common KRAS mutant variants. QTX3034 is a potent, highly selective, orally bioavailable allosteric multi-KRAS inhibitor that is efficacious against a broad spectrum of the more common KRASG12D- and KRASG12V-mutated cancers in vitro and in vivo. In an effort to enhance anti-tumor activity of QTX3034 and to minimize the development of possible resistance mechanisms, we explored the potential synergy of combining QTX3034 with EGFR inhibitors in multiple KRAS-mutated tumor models. Cell viability assays over a 7-day period revealed that QTX3034 synergized with three different EGFR inhibitors (afatinib, cetuximab, erlotinib) to profoundly inhibit proliferation across multiple KRASG12D, KRASG12V, and KRASWT Amp mutant cell lines with strong ZIP synergy scores (>10). Combination of QTX3034 and afatinib exhibited a markedly greater inhibitory effect on KRAS-mutant colony formation compared to the respective single agents. Analysis of RAS downstream signaling revealed that the combination of QTX3034 and afatinib produced a more potent suppression of the MAPK pathway than either single agent alone in KRAS-mutant cells. Moreover, QTX3034 monotherapy induced a dose-dependent increase in EGFR phosphorylation in the KRASG12D-mutated cell line GP2D, while co-administration with afatinib robustly inhibited this EGFR activation. Combining QTX3034 and cetuximab elicited durable tumor regressions in KRASG12D-mutant cell line-derived xenograft models. Furthermore, tumor regressions in these combination studies were obtained using meaningfully lower doses of QTX3034 than needed to achieve tumor regression by monotherapy. Similar combinations improved QTX3034 anti-tumor activity in patient-derived xenograft models that exceeded monotherapy with either agent. Taken together, these data support the rationale to co-administer QTX3034 and EGFR inhibitors to optimize therapeutic benefit for patients with KRAS-mutated cancers. Citation Format: Yang J. Zhang, Jillian M. Silva, Yang W. Zhang, Elizabeth Donohue Vo, John M. Micozzi, Douglas Krauth, Arghyotri Sinha, Ben Reid, Brooke McDonough, Gregory M. Lee, Christopher C. Pan, Audrey Hospital, Juan I. Luengo, Cameron Pitt, Hong Lin. QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr LB_C09.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
4秒前
Timon发布了新的文献求助10
5秒前
上官若男应助SXM采纳,获得10
6秒前
小马甲应助萤火虫采纳,获得10
7秒前
Xx发布了新的文献求助10
8秒前
10秒前
14秒前
嘎嘎发布了新的文献求助10
14秒前
十三发布了新的文献求助20
15秒前
zxx关闭了zxx文献求助
17秒前
瓦罐汤发布了新的文献求助10
18秒前
所所应助Xx采纳,获得10
19秒前
罗_应助加菲丰丰采纳,获得10
19秒前
干嘛鸭完成签到 ,获得积分10
24秒前
26秒前
pp完成签到,获得积分10
27秒前
30秒前
猪猪女孩一路硕博完成签到,获得积分10
30秒前
天天快乐应助科研通管家采纳,获得10
33秒前
田様应助科研通管家采纳,获得10
33秒前
充电宝应助科研通管家采纳,获得30
33秒前
大模型应助科研通管家采纳,获得10
33秒前
ok应助科研通管家采纳,获得10
33秒前
科研通AI2S应助科研通管家采纳,获得10
33秒前
33秒前
jz完成签到,获得积分10
34秒前
Vivi完成签到,获得积分10
35秒前
ivy发布了新的文献求助10
36秒前
无感完成签到 ,获得积分10
39秒前
桐桐应助ivy采纳,获得10
41秒前
41秒前
风生完成签到,获得积分10
43秒前
田恬完成签到,获得积分10
43秒前
44秒前
44秒前
46秒前
47秒前
希望天下0贩的0应助康2000采纳,获得10
49秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
《粉体与多孔固体材料的吸附原理、方法及应用》(需要中文翻译版,化学工业出版社,陈建,周力,王奋英等译) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3084988
求助须知:如何正确求助?哪些是违规求助? 2738035
关于积分的说明 7547906
捐赠科研通 2387624
什么是DOI,文献DOI怎么找? 1266055
科研通“疑难数据库(出版商)”最低求助积分说明 613267
版权声明 598450